us afternoon. for this Carrie, and thanks, joining everyone, Thanks,
we ramp closely thought Product footprint, key make progress Proteograph with of commercial strong business across our to and continue as our areas leaders. customers We work on installed all expand and Suite the base our
to balance in million positioned drive continuing to while on our plan. in sheet, research advance with capabilities We $XXX our quarter on remaining the strategic revenue at our plasma the show map of our power to scale, further and well expands unbiased the the As business execute multiyear data road of body momentum second we're our driving development of than cash proteomics technology. ended and million to more of $X.X
release, accumulation started six XX evidence a unlocking insights seeing customers unmet believe our results we're of our they never that phased Now more research applications, Across broad commercialization we significant months are and seeing since early of that biological promising needs. than range wide addresses our seen commercial months before. following are technology
that acquiring expected work translational majority projects diseases projects our and and number of among research the our see and of research a discovery, expanding other environment involve are customers' by and wide span research and the clinical aging These range applications. human pleased on cancer of impact biomarkers. clinically date, We To we in biomarker of span would across technology. the clinical are soon in early rejuvenation customers samples translational relevant cell clinical detection, an after complex undertaking relatively in customers discovery, or applications, health, to run studies
with XXXX Now our larger five some would our that beyond. in to growth and I key on updates execution to context, drive now objectives share like against
Proteograph road Product to to continuing and experience world systematically helping the of and fifth, map our for make nanoparticles; of our and our installed and out capabilities customers footprint; the team, around engineered across their applications proprietary reminder, customers efforts adopt to technology. markets for Suite objectives driving a scope; are: geographic for easier base commercial second, an supporting it build fourth, instruments; As enable while even use global and first, size product them customer our expanding with projects to third, increasing to scale our industry-leading expanding network of our more partnership these
updates. the to Now
genomics ASMS. spring our they're as Since Seer across examples and saw These making. Proteograph space at XXXX, first AACR, AGBT, conference United spanned as the additional and and such conferences. XX season, nine the ESHG the at included review progress and Let's as XX scientists of Asia. proteomics well specific States, events start posters how presentations we Europe posters busy quarter are scientific customers events have the and the our presented the with In industry and using customers some then, of conferences with
Importantly, about presentations X/X from these our customers. of were
Now you pretty period their customers relatively when the for remarkable a have labs time. Proteograph of most consider this had is that short our in of
Society the Proteograph new June, For interrogating in presentations previously there Proteograph American to the or at example, the Mass level, conference possible. the including early enabling approach and by a is Suite posters high our several Product and proteome most a depth were entirely an scale themes were, customers. Product Spectrometry, at first, multiple ASMS, Suite, not of At featuring common the
This high strong cancer biomarker of result moderate the pancreatic size in to observed biological enables of despite achieved cohort, PrognomIQ To in was for other in large-scale perform biological proteomics. researchers see this, across share is proteins, of able high-resolution access thousands driven with the low to And especially amino and cancer XXX signals that and necessary XX peptide- of biological a compared been had enable power study. the of studies multiple they across and Starting in signatures some among changes the unbiased technical very Second, this protein practical a that customers' signals is to similar noise cancer is published highlights found than see more low-abundance variant information, cohorts. proteome. they abundance pancreatic significant illustrate identification this to to biological through in to This they clinical proteome, breadth the possible signals novel exciting like to date. which by to proteins greatly studies statistically and protein part allowing relative signatures only proteogenomics the the predictive detection case-controlled and the PrognomIQ, multiomic of markers specific deep sample capability enabling due to healthy posters. size. third, from because in the Proteograph subjects I'd researchers acid-level their is with previously novel differences of
more You PrognomIQ this can Cancer mid-September. the at on upcoming study Pancreatic also AACR from Conference in hear
primarily accessible interrogation were Cornell and at workflows and The between to the what XX as unbiased global oxidative of they And the in a and proteins fully from scale. their independent consequence discovery differentially basis in of the X,XXX before known low-abundance of excited single-shot X,XXX drug as the data finally, Moving proteins, molecular civilian for also across astronauts therapeutics, used in the pathways. looking acquisition, Proteograph a abundant on more indicative to time in in a revealing that previously space a depth using a the question The at samples. for than more certain stress analysis proteins be and average, InspirationX which of poster unprecedented integrated collaboration crew, discovery four on holistic, excellence drug or presented protium stand-alone solutions, of leaders travel. samples, increasingly patient showed of of poster such SpaceX, detection of human of development by open-ended was They're to points deep poster not Evotec, detected protein with were proteins cytokines, class Seer, these DIA, findings, individual through Weill important metabolic or happens at level physiology a than flight. Seer after providing address one that, the center solutions highlighted an XXX space
Plasma of previously the to by information to which very abundant were complex is arbitrary the the protiome to additional at much, omic and posters proteome be Mann, that the XXX was an depth shallow titled be using and proteins be at by XXXX were biomarkers of historically, Proteomic" provides published at as was in of publication the Importantly, majority limited. readily correlates fractionation that protein Discovery of protocols. these how if that XXX in of to presented validated. immunodepletion This were X,XXX efficiently proteins. proposed without Proteograph authors be their the with of the what and by protein the biased and Biomarker XXX discovered unique leaders how interest. could highlight because, Suite workflows an protein scale, vast depth Matthias interrogated time changes a FDA-approved paper proteomics, The proposition one plasma evidence access most of this Professor the proteins In the biomarkers could scale "Revisiting could interrogated variance enable proteomic These the towards the known affected, may the other Proteograph value Product that
of early acid-level to to provides peptide- a see Here rapid reproducibility, this. level a is genomics in signature ahead. the of uniquely novel The variants. in protein expect and, at-scale this variants this the differences depth And or comprising possible have even deep and sizes, support to enabling from proteome to at plasma content. Mann's of is in and identify and been protein variants to of proteins it Larger proteome Proteograph to populations. proteomics the with enable resolution The in our more Customer the allow Proteograph why data the Seer and across cohorts very before expansion scale massive biomarkers, possible. and positioned possible novel discovery thus, amino combination complex novel are practical putative in the to [indiscernible] functionalization seeing on cohort more discovery of appears scale efficient significant power content We're of days genomic they and likely enables of and plasma Professor biology of made groups discovery, never statistically biomarker high protein I access understanding would deepening biomarkers are the and even finding depth hypothesis. small reveal changes making years
the months domain network will effect accelerating expect more adoption. a public As enters years, over coming it data have we third-party in the and
and We medicine. in progressively we spans applications, exciting we accelerate and our oncology, are infection. see health, growing disease diseases, of This broad a markets diseases, and adoption of reproductive strong and biomarker range of disease multiple families, including proteomics, discovery, veterinary including It early see unbiased deep the target other interest and in for across the complex clear disease neurodegenerative also interest Proteograph parallel, identification will is as across and gaining. is the drug a data broad range development need emergence a it's to there customer aging cardiovascular traction expect
Now installed growing base. turning to our
see qualified between of to roughly with academic geographies, interest our across pipeline strong continue customers. leads We and commercial equal
Suite. Suite. relative to submitted and shorter global and the percentage Europe projects. their how academic America, approved more increase Asia the Over is installed each commercial and base we to Product stated, the in risk cycle uncertainty segment our Despite Proteograph fundings expect our academic and expanding quarter, able of Product previously supply grants across our have we the prospect for were ongoing do as receives by in chain, around As time, customers increase driven prospects, for for the sales North to leveraging are to we the of base projects COVID the installed access Proteograph second more
recently Suite resolution an innovative added mass company, future has presence, Bertis, U.S. and development Proteograph scaling spec-based example, complement and and South an the proteomic-based by increasing accelerate scope to Korean medicine the translational test capabilities established As a discovery clinical the which the studies. Product precision of
of installation partnership reminder, and where deep proteomic Discovery capabilities we And will months Proteograph over and points the are as expansion essential Discovery of offer to existing first-of-its-kind SCIEX's and and submit set to multiyear facility expand studies Proteogenomics three our plan and proud XXXX their of validation study. to next of the genomic a insight a which, the in become for and new to an up with more data enters namely, we customers, first-of-its-kind the that proteogenomic believe them Boston are using up, enable received customer Sciences process to any a year-end. collaboration samples. the more is data manuscripts public for Consortium, samples services that body provide value Suite before in This XXX of instruments proposition the third-party developing at progress XXX,XXX capacity established novel domain of expect internal for is the the proteome into and in proof to a the coming generation over ZenoTOF We the SCIEX. a ramp with partnership, established. the is and of made area number annual multiomic Proteograph market their the Life phases important product. Discovery growing with will and We a as recently unbiased with the differentiated see Customer-driven finally, years, Product
streamlined, level expect protein projects will customer's variant accelerate fourth Proteogenomics begin early they of running as nearly year. We We operations any the at of as quarter the type that initial proteogenomics projects scaled, with expert the believe this Consortium customer match the will to needs.
is with PAS sample-specific in pushing disease databases. span software Suite, we're to we're genetic captured easily enabled range our data next expand to innovations variant software is nanoparticle-based methods. phenotype. lysate, understanding disruptive a at across the road importantly, technology what proteogenomic product, feature, mouse we the workflows, Proteograph nanoparticles future. enable proteomic meaningful to the extend our a across workflows and across of possible biomarker cell our that proprietary and access flexibility can management also variation by and to and of further expanding as organism, identify set peptide-level groups. X.X, closer assays Analysis engineered Product pig and empowers endpoints Proteograph move including not power also maps capabilities, footprint reference capabilities with enable As across moving Proteograph high-resolution as our of our types customer the model our elucidate a and, first-of-its-kind culture scale of With data including well uniquely would continuing genomic We're of the accessibility novel on version what the done exemplification X.X sample approach to the Suite. canonical workflows next for broad off This genomic functionalizing Customers proteogenomics Proteograph more to to data insight that be with not cell and standardizing workflow to platform. can innovations expand and peptides of peptide-level enabling and association, is discovery further the recent map streamlined mass-spec and informatics. We're with data and already lay These leverage proteogenomics, the globally proprietary the release targeted into of PAS something engineered of our
of flexibility, scientific this acceleration to expand expect community to the immense work see we work biological to insight. of unlock an As we the
against focus our will in stream that expand will them, and continuous committed content goals we to on providing I for execution drive As are improvement and the work set pace closely proteomics. a call now customers David. enhancement product our with With to customers, that, and access over we innovation turn of biological novel a to to
